Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma.
Yannick SimoniEtienne BechtShamin LiChiew Yee LohJoe Poh Sheng YeongTony Kiat Hon LimAngela TakanoDaniel Shao Weng TanEvan William NewellPublished in: Clinical & translational immunology (2020)
Epstein-Barr virus-specific CD8+ TILs in EBV-driven tumor are heterogeneous and partially lack PD-1 expression, suggesting that anti-PD1/PD-L1 immunotherapy may not be an appropriate strategy for disinhibiting EBV-specific cells in the treatment of LELC patients.
Keyphrases
- epstein barr virus
- diffuse large b cell lymphoma
- poor prognosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- induced apoptosis
- newly diagnosed
- cell cycle arrest
- binding protein
- prognostic factors
- oxidative stress
- patient reported outcomes
- cell proliferation
- pi k akt
- combination therapy
- replacement therapy
- patient reported